DOCSLIB.ORG

2015 Canada Gairdner Recipients’ Lecture University of Toronto – Macleod Auditorium Thursday, October 29, 2015; 9:00 Am – 3:00 Pm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2015 Canada Gairdner Recipients’ Lecture University of Toronto – Macleod Auditorium Thursday, October 29, 2015; 9:00 Am – 3:00 Pm 2015 Canada Gairdner Recipients’ Lecture University of Toronto – Macleod Auditorium Thursday, October 29, 2015; 9:00 am – 3:00 pm Thursday, October 30, 2014 Time Sessions and presentations’ Speakers titles 9:00 am – 9:05 am (5 mins) Opening Session – Welcome Dr. John Dirks, Remarks President & Scientific Director The Gairdner Foundation 9:05 am – 9:10 am (5 mins) Chairs & Dean’s Remarks Dr. Trevor Young, Dean, Faculty of Medicine University of Toronto 2015 Canada Gairdner Recipients’ Lectures 9:10 am - 9:45am (35mins) “Lessons from yeast – Molecular Dr. Yoshinori Ohsumi, Machinery of autophagy” 2015 Canada Gairdner International Laureate Tokyo Institute of Technology, Yokohama, Japan 9:45am – 10:20am (35 mins) “P1 3-Kinase and human disease” Dr. Lewis Cantley, 2015 Canada Gairdner International Laureate Weill Cornell Medical College, New York, NY, USA 10:20 am – 10:40 am (20 mins) Health Break 10:40 am -11: 15 am (35 mins) “TOR signaling in growth and Dr. Michael Hall, metabolism” 2015 Canada Gairdner International Laureate University of Basel, Basel, Switzerland 11:15 am-11:50 am (35 mins) “Regulatory T cells, a key controller Dr. Shimon Sakaguchi, of immune responses” 2015 Canada Gairdner International Laureate Osaka University, Osaka, Japan 11:50 am- 1:00 pm (by invitation only) Lunch/Networking 1:00 pm – 1:05 pm (5 mins) Introduction of speakers 1.05 pm – 1.40 pm (35 mins) “Nonsense-mediated mRNA decay Dr. Lynne Maquat, 2015 Canada Gairdner Recipients’ Lecture University of Toronto – Macleod Auditorium Thursday, October 29, 2015; 9:00 am – 3:00 pm and human disease: Genome 2015 Canada Gairdner International guardian and executor” Laureate, University of Rochester, Rochester, NY, USA 1:40 pm - 2:15 pm (35 mins) “Making the blastocyst – from cells to Dr. Janet Rossant, genes to stem cells” 2015 Canada Gairdner Wightman Laureate, The Hospital for Sick Children, Toronto, ON 2:15 pm - 2:50 pm (35mins) “Lessons from Ebola and AIDS for Dr. Peter Piot, global health” 2015 Canada Gairdner Global Health Laureate, Director, London School of Hygiene & Tropical Medicine, London, UK 2:50 pm – 3:00 pm (10 mins) Closing Remarks Dr. John Dirks, President & Scientific Director, The Gairdner Foundation 2015 Gairdner Symposium “RNA and The New Genetics” University of Toronto – MacLeod Auditorium Friday, October 30, 2015 – 8.45 a.m. – 3.30 p.m. Friday, October 30, 2015 Time Sessions and Research overview Speakers presentations’ titles 8:45 am – 8:55 am Opening Session – Dr. John Dirks, M.D., Welcome Remarks President and Scientific Director The Gairdner Foundation 8:55 am – 9:10 am General introduction about Made seminal contributions Dr. Lynne Maquat, Ph.D., non-coding RNAs and on mechanisms of nonsense- Director of the Center for RNA ethical issues of genome mediated messenger RNA Biology: From Genome to editing manipulation in decay (NMD) and another Therapeutics, and Professor of human embryo. pathway she discovered and Biochemistry and Biophysics, named Staufen-mediated University of Rochester School of mRNA decay (SMD). Medicine and Dentistry, J. Lowell Orbison Endowed Chair; 2015 Canada Gairdner International Awardee Noncoding RNA 9:10 am – 9:40 am The origins and functions Dr. Phillip Sharp, Ph.D., of non-coding RNAs. Institute Professor Koch Institute for Integrative Cancer Research, MIT; Gairdner awardee; Nobel Laureate in Physiology or Medicine 9:40 am – 10:10 am Genome regulation by Describes long noncoding Dr. Howard Chang, M.D., Ph.D., noncoding RNAs. RNAs are key players in the Professor of Dermatology development of disease. Director, Center for Personal Dynamic Regulomes; Stanford University School of Medicine 10:10 am – 10:30 am Health Break RNA-mediated Epigenetics 2015 Gairdner Symposium “RNA and The New Genetics” University of Toronto – MacLeod Auditorium Friday, October 30, 2015 – 8.45 a.m. – 3.30 p.m. 10:30 am – 11:00 am Regulatory interactions Characterizes long Dr. Jeannie Lee, M.D., Ph.D., between long noncoding noncoding RNA-mediated Professor of Genetics and Pathology RNA and epigenetic epigenetic regulation, Harvard Medical School, complexes. including X-chromosome Massachusetts General Hospital inactivation. Investigator, HHMI Pre-mRNA Splicing 11:00 am – 11:30 am Alternative splicing Made pioneering Dr. Benjamin Blencowe, Ph.D., regulatory networks and contributions to the discovery Professor their roles in and characterization of Banbury Chair in Medical Research neurodevelopmental alternative splicing Department of Molecular Genetics; disorders regulatory networks and is University of Toronto currently focusing on the role of these networks in the control of cell fate and neurological disorders. microRNAs 11:30 am – 12:00 pm New mechanisms of Investigates the regulation Dr. Joshua Mendell, M.D., Ph.D., noncoding RNA regulation and function of microRNAs, Professor of Molecular Biology and function. with a focus on potentially Member, Center for Regenerative important roles for Science and Medicine microRNAs in normal Member, Simmons Cancer Center physiology and in the UT Southwestern Medical Center development of cancer. Investigator, HHMI 12:00 pm – 1:00 pm Lunch/Networking CRISPR/Cas 1:00 pm – 1:30 pm Biology, mechanisms and Characterizes gene Dr. Emmanuelle Charpentier, Ph.D., applications of CRISPR- regulatory mechanisms in Professor and Departmental Head Cas9: a game changer in infection and immunity, Regulation in Infection Biology genome engineering. including Cas9 as a powerful Hannover Medical School Helmholtz tool for genome editing. Centre for Infection Research Braunschweig, Germany 1:30 pm – 2:00 pm Development of CRISPR- Develops molecular Dr. Feng Zhang, Ph.D., Cas9 for Genome technologies for controlling Core Member Engineering cellular function, including Broad Institute of MIT and Harvard harnessing CRISPR-Cas as a Investigator new genome-editing tool for McGovern Institute for Brain eukaryotic cells Research W. M. Keck Career Development 2015 Gairdner Symposium “RNA and The New Genetics” University of Toronto – MacLeod Auditorium Friday, October 30, 2015 – 8.45 a.m. – 3.30 p.m. Professor Departments of Brain and Cognitive Sciences and Biological Engineering; MIT 2:00 pm – 2:20 pm Health break Commentary 2:20 pm – 2:50 pm The Science, Safety, and Investigates RNA-based gene Dr. Erik Sontheimer, Ph.D., Ethics of Genome Editing regulation biology and Professor at the RNA Therapeutics mechanisms; CRISPR Institute interference; RNA-directed University of Massachusetts Medical genome editing and gene School control 2:50 pm – 3:20 pm Round table Discussion All speakers + Dr. Lynne Maquat 3:20 pm – 3:30 pm Closing Remarks Dr. John Dirks, M.D., President and Scientific Director The Gairdner Foundation 1. A world leader of research in molecular biology and biochemistry, Dr. Phillip A. Sharp is Institute Professor at the Massachusetts Institute of Technology. Much of Dr. Sharp's scientific work has been conducted at MIT's Center for Cancer Research (now the Koch Institute), which he joined in 1974 and directed from 1985 to 1991. He subsequently led the Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000-2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark achievement was the discovery of RNA splicing in 1977. This work provided one of the first indications of the startling phenomenon of “discontinuous genes” in mammalian cells. The discovery that genes contain nonsense segments that are edited out by cells in the course of utilizing genetic information is important in understanding the genetic causes of cancer and other diseases. This discovery, which fundamentally changed scientists' understanding of the structure of genes, earned Dr. Sharp the 1993Nobel Prize in Physiology or Medicine. His lab has now turned its attention to understanding how RNA molecules act as switches to turn genes on and off (RNA interference). These newly discovered processes have 2015 Gairdner Symposium “RNA and The New Genetics” University of Toronto – MacLeod Auditorium Friday, October 30, 2015 – 8.45 a.m. – 3.30 p.m. revolutionized cell biology and could potentially generate a new class of therapeutics. Dr. Sharp has authored over 385 scientific papers. He has received numerous awards and honorary degrees, and has served on many advisory boards for the government, academic institutions, scientific societies, and companies. His awards include the Gairdner Foundation International Award, General Motors Research Foundation Alfred P. Sloan, Jr. Prize for Cancer Research, the Albert Lasker Basic Medical Research Award, the National Medal of Science and the inaugural Double Helix Medal from CSHL. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and is a Foreign Fellow of the Royal Society, UK. A native of Kentucky, Dr. Sharp earned a B.A. degree from Union College, KY in 1966, and a PhD in chemistry from the University of Illinois, Champaign-Urbana in 1969. He did his postdoctoral training at the California Institute of Technology, where he studied the molecular biology of plasmids from bacteria in Professor Norman Davidson's laboratory. Prior to joining MIT, he was Senior Scientist at Cold Spring Harbor Laboratory. In 1978 Dr. Sharp co-founded Biogen (now Biogen Idec) and in 2002 he co-founded Alnylam Pharmaceuticals, an early-stage therapeutics company. 2. Howard Y. Chang M.D., Ph.D. is Professor of Dermatology and Director of the Center for Personal Dynamic Regulomes at Stanford University School of Medicine. Chang earned a Ph.D. in Biology from MIT, M.D. from Harvard Medical School, and completed Dermatology residency and postdoctoral training at Stanford University. His research addresses how large sets of genes are turned on or off together, which is important in normal development, cancer, and aging. Chang discovered a new class of genes, termed long noncoding RNAs, can control gene activity throughout the genome, illuminating a new layer of biological regulation.
Load more

Recommended publications
  • Optogenetics: Using Light to Control the Brain by Edward S. Boyden, Ph.D
    Optogenetics: Using Light to Control the Brain By Edward S. Boyden, Ph.D. Courtesy of the MIT McGovern Institute, Julie Pryor, Charles Jennings, Sputnik Animation, and Ed Boyden. Editor’s note: The brain is densely packed with interconnected neurons, but until about six years ago, it was difficult for researchers to isolate neurons and neuron types to determine their individual roles in brain processes. In 2004 however, scientists, including author Edward S. Boyden, Ph.D., found that the neural expression of a protein, channelrhodopsin-2 (ChR2), allowed light to activate or silence brain cells. This technology, now known as optogenetics, is helping scientists determine the functions of specific neurons in the brain, and could play a significant role in treating medical issues as diverse as sleep disorders and vision impairment. Article available online at http://dana.org/news/cerebrum/detail.aspx?id=34614 1 The brain is an incredibly densely wired computational circuit, made out of an enormous number of interconnected cells called neurons, which compute using electrical signals. These neurons are heterogeneous, falling into many different classes that vary in their shapes, molecular compositions, wiring patterns, and the ways in which they change in disease states. It is difficult to analyze how these different classes of neurons work together in the intact brain to mediate the complex computations that support sensations, emotions, decisions, and movements—and how flaws in specific neuron classes result in brain disorders. Ideally, one would study the brain using a technology that would enable the control of the electrical activity of just one type of neuron, embedded within a neural circuit, in order to determine the role that that type of neuron plays in the computations and functions of the brain.
    [Show full text]
  • Mechanical Aspire
    Newsletter Volume 6, Issue 11, November 2016 Mechanical Aspire Achievements in Sports, Projects, Industry, Research and Education All About Nobel Prize- Part 35 The Breakthrough Prize Inspired by Nobel Prize, there have been many other prizes similar to that, both in amount and in purpose. One such prize is the Breakthrough Prize. The Breakthrough Prize is backed by Facebook chief executive Mark Zuckerberg and Google co-founder Sergey Brin, among others. The Breakthrough Prize was founded by Brin and Anne Wojcicki, who runs genetic testing firm 23andMe, Chinese businessman Jack Ma, and Russian entrepreneur Yuri Milner and his wife Julia. The Breakthrough Prizes honor important, primarily recent, achievements in the categories of Fundamental Physics, Life Sciences and Mathematics . The prizes were founded in 2012 by Sergey Brin and Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, Yuri and Julia Milner, and Jack Ma and Cathy Zhang. Committees of previous laureates choose the winners from candidates nominated in a process that’s online and open to the public. Laureates receive $3 million each in prize money. They attend a televised award ceremony designed to celebrate their achievements and inspire the next generation of scientists. As part of the ceremony schedule, they also engage in a program of lectures and discussions. Those that go on to make fresh discoveries remain eligible for future Breakthrough Prizes. The Trophy The Breakthrough Prize trophy was created by Olafur Eliasson. “The whole idea for me started out with, ‘Where do these great ideas come from? What type of intuition started the trajectory that eventually becomes what we celebrate today?’” Like much of Eliasson's work, the sculpture explores the common ground between art and science.
    [Show full text]
  • Annual Report Fy 2018 Human Frontier Science Program Organization
    APRIL 2017 APRIL 2018 — MARCH 2019 ANNUAL REPORT FY 2018 HUMAN FRONTIER SCIENCE PROGRAM ORGANIZATION The Human Frontier Science Program Organization (HFSPO) is unique, supporting international collaboration to undertake innovative, risky, basic research at the frontier of the life sciences. Special emphasis is given to the support and training of independent young investigators, beginning at the postdoctoral level. The Program is implemented by an international organisation, supported financially by Australia, Canada, France, Germany, India, Italy, Japan, the Republic of Korea, New Zealand, Norway, Singapore, Switzerland, the United Kingdom of Great Britain and Nothern Ireland, the United States of America, and the European Commission. Since 1990, over 7000 researchers from more than 70 countries have been supported. Of these, 28 HFSP awardees have gone on to receive the Nobel Prize. 2 The following documents are available on the HFSP website www.hfsp.org: Joint Communiqués (Tokyo 1992, Washington 1997, Berlin 2002, Bern 2004, Ottawa 2007, Canberra 2010, Brussels 2013, London 2016): https://www.hfsp.org/about/governance/membership Statutes of the International Human Frontier Science Program Organization: https://www.hfsp.org/about/governance/hfspo-statutes Guidelines for the participation of new members in HFSPO: https://www.hfsp.org/about/governance/membership General reviews of the HFSP (1996, 2001, 2006-2007, 2010, 2018): https://www.hfsp.org/about/strategy/reviews Updated and previous lists of awards, including titles and abstracts:
    [Show full text]
  • View Final Program
    142nd ANNUAL MEETING OF THE AMERICAN ANA2017 NEUROLOGICAL ASSOCIATION SAN DIEGO, CA • OCTOBER 15-17, 2017 SHERATON SAN DIEGO HOTEL & MARINA EXPLORE • EXAMINE • INVESTIGATE FINAL PROGRAM OCTOBER 14, 2017 | Pre-Meeting Symposium: Big Science and the BRAIN Initiative 2017.MYANA.org 142nd ANNUAL MEETING OF THE AMERICAN ANA2017 NEUROLOGICAL ASSOCIATION SAN DIEGO, CA • OCTOBER 15 -17, 2017 SHERATON SAN DIEGO HOTEL & MARINA ND Please note some session titles may have changed since this program was printed. Please refer THE 142 ANA to your Mobile app for the most current session updates. ANNUAL MEETING LETTER FROM THE CHAIR 3 Enjoy outstanding scientific SCHEDULE AT A GLANCE 4 symposia covering the latest HOTEL FLOOR PLANS 6 research in the fields of neurology and neuroscience GENERAL INFORMATION 7 while taking the opportunity WIRELESS CONNECTION 8 to network with leaders in the world of academic neurology CONTINUING MEDICAL EDUCATION 8 at the 142nd ANA Annual ANNUAL MEETING MOBILE APP 8 Meeting in San Diego, CA, October 15-17, 2017. PROGRAMS BY DAY 9 SATURDAY OCT 14 9 MEETING LOCATION SUNDAY OCT 15 9 Sheraton San Diego MONDAY OCT 16 17 Hotel & Marina 1380 Harbor Island Drive TUESDAY OCT 17 25 San Diego, California 92101 IN MEMORIAM 28 ONSITE MEETING CONTACTS SPEAKER ABSTRACTS 29 Registration and meeting questions: THANK YOU TO OUR SUPPORTERS & EXHIBITORS 42 [email protected] FUTURE MEETING DATES 42 OR visit the registration desk Bay View Foyer 2017 AWARDEES 43 (located in Marina Tower Lobby Level) ACADEMIC NEUROLOGY REPRESENTATIVES FROM JAPAN 47 Saturday, October 14 2017 ABSTRACT REVIEWERS 48 3:00 PM–7:00 PM BOARD OF DIRECTORS 49 Sunday, October 15 6:00 AM–5:45 PM ANA 2017 COMMITTEES, SUBCOMMITTEES & TASK FORCES 50 Monday, October 16 6:30 AM–5:45 PM Tuesday, October 17 6:30 AM–2:15 PM #ANAMTG2017 ANA 2017 FROM THE CHAIR Dear Colleagues, It is a pleasure to welcome you to the 142nd Annual Meeting of the American Neurological Association (ANA).
    [Show full text]
  • Issue 17: Pushing the Frontiers Of
    Br aın SCAN mcgovern institute for brain research at mit Issue no. 17 Summer 2010 From the director In this issue we highlight the work of Alan Jasanoff, who is developing imaging technologies that will provide an entirely new view of brain activity. Magnetic resonance imaging (MRI) has been critical to our understanding of brain function, and Alan Jasanoff is working to take this technology to an entirely new level. He is designing new molecular sensors that can reveal far more about brain activity than conventional functional MRI, which is based on changes in blood flow and oxygen levels within the brain. Alan’s work draws on nuclear engineering, protein engineering, chemistry and cognitive neuroscience, and exemplifies the interdisciplinary approach that is at the heart of our mission. I am also pleased to announce the appointment of a new faculty member, Feng Zhang, who will be joining the McGovern Institute in January 2011. Feng, who received his PhD from Stanford University and who is now a Harvard Junior Fellow, is an expert on optogenetics and stem cell applications. I am especially pleased that, in addition to his appointment Cover art: in the McGovern Institute and the Department Feng Zhang, who of Brain and Cognitive Sciences, Feng will also be will join the Institute in 2011, is an expert a core faculty member of the Broad Institute. His Alan Alda and Jane Pauley–and by our longtime in manipulating brain appointment strengthens our ties to the world’s friend and advisor Gerald Fischbach, scientific activity with light. foremost center for genomics research in medicine.
    [Show full text]
  • 2020 Stanford Bio-X Fellowship Brochure
    STANFORD BIO-X PHD FELLOWSHIPS 2020 Stanford Bio-X Fellows Group Photo 2019 The Stanford Bio-X Graduate Fellowships The mission of the Stanford Bio-X Program is to catalyze discovery by crossing the boundaries between disciplines to bring interdisciplinary solutions, to create new knowl- edge of biological systems, and to benefit human health. Since it was established in 1998, Stanford Bio-X has charted a new approach to life science research by bringing together clinical experts, life scientists, engineers, and others to tackle the complexity of the human body. Currently over 980 Stanford Faculty and over 8,000 students, postdocs, researchers, etc. are affiliated with Stanford Bio-X. The generous support from donors, including the Bowes Foundation, enables the program to remain successful—at any given time, Stanford Bio-X is training at least 60 Ph.D fellows, and Fall 2020 brings 21 new fellows to the program. The Stanford Bio-X Graduate Fellowship Program was started to answer the need for training a new breed of visionary science leaders capable of crossing the bound- aries between disciplines in order to bring novel research endeavors to fruition. Since its inception in 2004, the three-year fellowships, including the Stanford Bio-X Bowes Fellowships and the Bio-X Stanford Interdisciplinary Graduate Fellowships (Bio-X SIGFs), have provided 318 graduate students with awards to pursue interdisciplinary research and to collaborate with multiple mentors, enhancing their potential to gen- erate profound transformative discoveries. Stanford Bio-X Fellows become part of a larger Stanford Bio-X community of learning that encourages their further networking and development.
    [Show full text]
  • CV Karl Deisseroth
    Curriculum Vitae Prof. Dr. Karl Deisseroth Name: Karl Deisseroth Born: 18 November 1971 Main areas of research: Optogenetics, CLARITY method (Clear Lipid-exchanged Anatomically Rigid/Immunostaining-compatible Tissue Hydrogel), Channelrhodopsin, Channelrhodopsin-2, neurological diseases, depression, autism diseases Karl Deisseroth is a US American psychiatrist and neuroscientist. He was one of the founders of optogenetics and also developed the CLARITY method. Unimagined insights into the brain have been gained through the use of both methods. Deisseroth hopes that these will then lead to a greater understanding of neurological diseases. Academic and professional career since 2014 Investigator at the Howard Hughes Medical Institute (HHMI), Maryland, USA since 2013 Extraordinary Professor, Karolinska Institutet, Sweden since 2012 D.H. Chen Professor of Bioengineering, Psychiatry and Behavioral Research, Stanford University, USA since 2012 Professor of Bioengineering and Psychiatry, Stanford 2009 - 2013 HHMI Early Career Investigator 2009 - 2012 Associate Professor of Bioengineering and Psychiatry, Stanford University 2005 - 2008 Assistant Professor of Bioengineering und Psychiatry, Stanford University 2004 - 2005 Principal Investigator and Clinical Educator, Institute of Psychiatry, Stanford University School of Medicine 2000 - 2004 Assistant physician in Psychiatry, Stanford University 2000 - 2001 MD internship/licensure, Stanford University Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 1994 - 1998 Ph.D. Stanford
    [Show full text]
  • Gabbay20program.Pdf
    JACOB AND LOUISE GABBAY AWARD IN BIOTECHNOLOGY AND MEDICINE JACOB AND LOUISE JACOB AND LOUISE GABBAY AWARDGABBAY AWARD IN BIOTECHNOLOGY IN BIOTECHNOLOGYAND MEDICINE AND MEDICINE PRESENTATION CEREMONY 20th WEDNESDAY, OCTOBER 18, 2017 Annual WALTHAM, MASS. BRANDEIS UNIVERSITY Early in 1998, the trustees of the Jacob and Louise Gabbay Foundation decided to establish a major new award in basic and applied biomedical sciences. The foundation felt that existing scientific awards tended to honor people who were already well-recognized or to focus on work that had its primary impact in traditional basic research fields. Yet the history of science suggests that most scientific revolu- tions are sparked by advances in practical areas such as instrumentation and techniques or through entrepreneurial endeavors. The foundation therefore created the Jacob Heskel Gabbay Award in Biotechnology and Medicine to recognize, as early as possible in their careers, scientists in academia, medicine or industry whose work had both outstanding scientific content and significant practical consequences in the biomedical sciences. The award was renamed the Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2016 to honor Jacob’s wife, Louise Gabbay, who was instrumental in founding the award. Because of their long association with Brandeis University, the trustees of the foundation asked the Rosenstiel Basic Medical Sciences Research Center at Brandeis to administer the award. The award, given annually, consists of a $15,000 cash prize (to be shared in the case of multiple winners) and a medallion. The honorees travel to Brandeis University each fall to present lectures on their work and attend a dinner at which the formal commendation takes place.
    [Show full text]
  • Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2016 to Honor Jacob’S Wife, Louise Gabbay, Who Was Instrumental in Founding the Award
    JACOB AND LOUISE JACOB AND LOUISE GABBAY AWARDGABBAY AWARD IN BIOTECHNOLOGY IN BIOTECHNOLOGYAND MEDICINE AND MEDICINE PRESENTATION CEREMONY 19th THURSDAY, SEPTEMBER 29, 2016 Annual WALTHAM, MASS. BRANDEIS UNIVERSITY Early in 1998, the trustees of the Jacob and Louise Gabbay Foundation decided to establish a major new award in basic and applied biomedical sciences. The foundation felt that existing scientific awards tended to honor people who were already well-recognized or to focus on work that had its primary impact in traditional basic research fields. Yet the history of science suggests that most scientific revolu- tions are sparked by advances in practical areas such as instrumentation and techniques or through entrepreneurial endeavors. The foundation therefore created the Jacob Heskel Gabbay Award in Biotechnology and Medicine to recognize, as early as possible in their careers, scientists in academia, medicine or industry whose work had both outstanding scientific content and significant practical consequences in the biomedical sciences. The award was renamed the Jacob and Louise Gabbay Award in Biotechnology and Medicine in 2016 to honor Jacob’s wife, Louise Gabbay, who was instrumental in founding the award. Because of their long association with Brandeis University, the trustees of the foundation asked the Rosenstiel Basic Medical Sciences Research Center at Brandeis to administer the award. The award, given annually, consists of a $15,000 cash prize (to be shared in the case of multiple winners) and a medallion. The honorees travel to Brandeis University each fall to present lectures on their work and attend a dinner at which the formal commendation takes place. This year, a committee of distinguished scientists selected Jeffery Kelly of the Scripps Research Institute for his profound and paradigm-shifting contri- butions to our understanding of protein-folding mechanisms and protein-folding diseases.
    [Show full text]
  • The BBVA Foundation Frontiers of Knowledge Award Goes to the Architects of Optogenetics, Which Uses Light to Probe and Modulate the Workings of the Brain
    Three neuroscientists win the Biomedicine award The BBVA Foundation Frontiers of Knowledge Award goes to the architects of optogenetics, which uses light to probe and modulate the workings of the brain Edward Boyden, Karl Deisseroth and Gero Miesenböck developed and refined a technique that employs light to activate and inactivate proteins in the brain cells, making it possible to modulate their activity with unprecedented precision Optogenetics is now a widely used tool being applied to elucidate functions like sleep, appetite and movement or reward circuits in addiction The awardees all emphasize the basic knowledge underpinning the technique, which, they say, will eventually yield new opportunities in the clinic Madrid, January 26, 2016.- The BBVA Foundation Frontiers of Knowledge Award in Biomedicine goes in this eighth edition to neuroscientists Edward Boyden, Karl Deisseroth and Gero Miesenböck for the development of optogenetics, a method to study brain function with unprecedented resolution. In a bare five years, thousands of groups the world over have begun using optogenetics to investigate functions like sleep, appetite, decision-making, temporal perception or the creation of memories, and elucidate the mechanisms of conditions such as epilepsy, Parkinson’s, depression and certain forms of blindness. The beauty of optogenetics is that it allows the selective control of neural activity simply by applying light of the right wavelength. Before, the most widely used methods to study the living brain could modulate the activity of hundreds of thousands of neurons, but with little selectivity. With optogenetics, it is possible to act exclusively on neurons treated previously with light-sensitive proteins, according to the behavior being tested.
    [Show full text]
  • From Cells to Circuits, Toward Cures Catherine Dulac, Ph.D
    Interim Update to the Advisory Committee to the NIH Director From Cells to Circuits, Toward Cures Catherine Dulac, Ph.D. John Maunsell, Ph.D. Co-Chairs December 14, 2018 A focus on circuits and networks “The challenge is to map the circuits of the brain, measure the fluctuating patterns of electrical and chemical activity flowing within those circuits, and understand how their interplay creates our unique cognitive and behavioral capabilities.” BRAIN 2025 (June 2014) Presentation Outline • Charge and Process • Assessment by Priority Area • Summary 3 Presentation Outline Charge and Process 4 Charge to Working Group 2.0 • Review BRAIN Initiative activities and progress • Suggest tune-ups to specific goals based on the evolving scientific landscape • Identify new opportunities for research and technology development as well as large transformative projects • Consider opportunities to train, empower and diversify a broader neuroscience research community 5 Working Group Roster • Catherine Dulac (Co-Chair), Harvard • Bruce Rosen, MGH • John Maunsell (Co-Chair), U Chicago • Krishna Shenoy, Stanford • David Anderson, Caltech • Doris Tsao, Caltech • Polina Anikeeva, MIT • Huda Zoghbi, Baylor • Paola Arlotta, Harvard Ex Officio: • Anne Churchland, CSHL • James Deshler, NSF • Karl Deisseroth, Stanford Alfred Emondi, DARPA • Tim Denison, Medtronic/Oxford • Christine Grady, Bioethics, NIH • Kafui Dzirasa, Duke U • • Lyric Jorgenson, NIH • Adrienne Fairhall, U Washington David Markowitz, IARPA • Elizabeth Hillman, Columbia • Carlos Peña, FDA • Lisa
    [Show full text]
  • Joshua T. Vogelstein –
    Joshua T. Vogelstein, Ph.D., Assistant Professor, JHU – Curriculum Vitae 2021/09/23 Assistant Professor, Department of Biomedical Engineering Johns Hopkins University B [email protected] Joshua T. Vogelstein Í jovo.me Personal Information Primary Appointment 08/14 – Assistant Professor, Department of Biomedical Engineering, JHU, Baltimore, MD, USA. Joint Appointments 09/19 – Joint Appointment, Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA. 08/15 – Joint Appointment, Department of Applied Mathematics and Statistics, JHU, Baltimore, MD, USA. 08/14 – Joint Appointment, Department of Neuroscience, JHU, Baltimore, MD, USA. 08/14 – Joint Appointment, Department of Computer Science, JHU, Baltimore, MD, USA. Institutional and Center Appointments 08/15 – Steering Committee, Kavli Neuroscience Discovery Institute (KNDI), Baltimore, MD, USA. 08/14 – Core Faculty, Institute for Computational Medicine, JHU, Baltimore, MD, USA. 08/14 – Core Faculty, Center for Imaging Science, JHU, Baltimore, MD, USA. 08/14 – Assistant Research Faculty, Human Language Technology Center of Excellence, JHU, Balti- more, MD, USA. 10/12 – Affiliated Faculty, Institute for Data Intensive Engineering and Sciences, JHU, Baltimore, MD, USA. Education & Training 2003 – 2009 Ph.D in Neuroscience, Johns Hopkins School of Medicine, Advisor: Eric Young, Thesis: OOPSI: a family of optical spike inference algorithms for inferring neural connectivity from population calcium imaging . 2009 – 2009 M.S. in Applied Mathematics & Statistics, Johns Hopkins University. 1998 – 2002 B.A. in Biomedical Engineering, Washington University, St. Louis. Academic Experience 08/18 – Director of Biomedical Data Science Focus Area, Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. 05/16 – Visiting Scientist, Howard Hughes Medical Institute, Janelia Research Campus, Ashburn, VA, USA.
    [Show full text]